AbCellera Biologics (ABCL) Financials

$4.82 -0.22 (-4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$4.92 +0.10 (+2.07%)

As of 07:54 PM Eastern

Annual Income Statements for AbCellera Biologics

This table shows AbCellera Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-2.21	119	153	159	-146	-163	-146
Consolidated Net Income / (Loss)	-2.21	119	153	159	-146	-163	-146
Net Income / (Loss) Continuing Operations	-2.21	119	153	159	-146	-163	-146
Total Pre-Tax Income	-2.21	158	219	239	-174	-200	-178
Total Operating Income	-4.12	156	204	217	-237	-315	-217
Total Gross Profit	12	233	375	485	38	29	75
Total Revenue	12	233	375	485	38	29	75
Operating Revenue	12	233	375	485	38	29	75
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	16	69	171	269	275	344	292
Selling, General & Admin Expense	2.75	12	42	55	75	85	83
Research & Development Expense	10	29	62	108	176	167	187
Depreciation Expense	1.60	4.84	14	28	24	91	22
Total Other Income / (Expense), net	1.91	-6.52	15	23	63	114	40
Interest & Investment Income	0.16	0.29	3.33	16	42	38	28
Other Income / (Expense), net	1.75	-6.81	11	6.51	21	76	11
Income Tax Expense	0.00	39	66	81	-28	-38	-31
Basic Earnings per Share	($0.01)	$0.53	$0.56	$0.56	($0.51)	($0.55)	($0.49)
Weighted Average Basic Shares Outstanding	151.33M	159.20M	275.76M	285.06M	289.17M	294.33M	298.71M
Diluted Earnings per Share	($0.01)	$0.45	$0.48	$0.50	($0.51)	($0.55)	($0.49)
Weighted Average Diluted Shares Outstanding	151.33M	263.13M	318.29M	314.83M	289.17M	294.33M	298.71M
Weighted Average Basic & Diluted Shares Outstanding	-	-	283.92M	287.69M	292.78M	297.99M	303.16M

This table shows AbCellera Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-30	-28	-48	-41	-37	-51	-35	-46	-35	-57	-8.95
Consolidated Net Income / (Loss)	-31	-29	-47	-41	-37	-51	-34	-46	-35	-57	-8.95
Net Income / (Loss) Continuing Operations	-31	-29	-47	-41	-37	-51	-34	-46	-35	-57	-8.95
Total Pre-Tax Income	-38	-39	-49	-43	-48	-63	-47	-53	-36	-69	-19
Total Operating Income	-51	-55	-66	-55	-93	-94	-73	-63	-50	-76	-29
Total Gross Profit	10	6.60	9.18	9.95	7.32	6.51	5.05	4.24	17	8.96	45
Total Revenue	10	6.60	9.18	9.95	7.32	6.51	5.05	4.24	17	8.96	45
Operating Revenue	10	6.60	9.18	9.95	7.32	6.51	5.05	4.24	17	8.96	45
Total Operating Expenses	61	61	75	65	101	100	78	67	67	85	73
Selling, General & Admin Expense	16	14	16	17	20	19	16	16	19	22	26
Research & Development Expense	36	38	49	39	41	41	46	42	39	55	50
Depreciation Expense	5.61	5.74	7.54	4.84	37	37	13	5.33	5.47	5.25	6.12
Total Other Income / (Expense), net	13	16	17	12	45	31	26	9.68	13	7.51	9.08
Interest & Investment Income	11	11	11	10	9.80	9.60	8.67	8.05	7.59	6.77	5.92
Other Income / (Expense), net	2.61	4.87	6.48	1.75	35	21	17	1.63	5.65	0.75	3.16
Income Tax Expense	-7.48	-11	-1.45	-2.14	-11	-12	-13	-7.36	-1.62	-12	-11
Basic Earnings per Share	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)	($0.15)	($0.12)	($0.19)	($0.03)
Weighted Average Basic Shares Outstanding	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M	297.69M	298.51M	298.88M	298.71M
Diluted Earnings per Share	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)	($0.15)	($0.12)	($0.19)	($0.03)
Weighted Average Diluted Shares Outstanding	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M	297.69M	298.51M	298.88M	298.71M
Weighted Average Basic & Diluted Shares Outstanding	289.36M	290.17M	292.78M	294.05M	294.67M	295.37M	297.99M	298.48M	298.83M	299.34M	303.16M

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-2.89	587	-93	-86	-254	23	-28
Net Cash From Operating Activities	2.69	23	245	277	-44	-109	-131
Net Cash From Continuing Operating Activities	2.69	23	245	277	-44	-109	-131
Net Income / (Loss) Continuing Operations	-2.21	119	153	159	-146	-163	-146
Consolidated Net Income / (Loss)	-2.21	119	153	159	-146	-163	-146
Depreciation Expense	1.60	2.32	4.40	8.95	13	13	18
Amortization Expense	0.24	2.95	13	24	18	84	10
Non-Cash Adjustments To Reconcile Net Income	1.08	13	34	56	58	-17	57
Changes in Operating Assets and Liabilities, net	1.97	-115	40	30	13	-26	-71
Net Cash From Investing Activities	-5.78	-120	-332	-353	-221	121	88
Net Cash From Continuing Investing Activities	-5.78	-120	-332	-353	-221	121	88
Purchase of Property, Plant & Equipment	-4.00	-9.67	-58	-71	-77	-78	-43
Acquisitions	0.00	-112	-42	-28	-14	-20	-7.14
Purchase of Investments	0.00	1.78	-292	-781	-1,067	-754	-453
Sale and/or Maturity of Investments	-1.78	0.00	28	511	911	938	539
Other Investing Activities, net	0.00	0.00	33	16	25	36	51
Net Cash From Financing Activities	0.20	684	-3.89	-1.63	10	13	14
Net Cash From Continuing Financing Activities	0.20	684	-3.89	-1.63	10	13	14
Other Financing Activities, net	0.03	90	-3.89	-1.63	10	13	14
Effect of Exchange Rate Changes	0.00	-	-1.43	-9.60	0.59	-2.62	1.10

This table details how cash moves in and out of AbCellera Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-13	-7.33	-39	-9.75	25	-22	30	2.94	-67	-9.28	45
Net Cash From Operating Activities	20	-0.11	-20	-42	-30	-29	-8.00	-12	-32	-53	-35
Net Cash From Continuing Operating Activities	20	-0.11	-20	-42	-30	-29	-8.00	-12	-32	-53	-35
Net Income / (Loss) Continuing Operations	-31	-29	-47	-41	-37	-51	-34	-46	-35	-57	-8.95
Consolidated Net Income / (Loss)	-31	-29	-47	-41	-37	-51	-34	-46	-35	-57	-8.95
Depreciation Expense	2.95	3.06	3.88	3.16	3.45	3.83	2.10	4.41	4.54	4.31	5.18
Amortization Expense	4.30	4.35	5.23	3.61	35	34	12	2.20	2.52	2.93	2.74
Non-Cash Adjustments To Reconcile Net Income	16	20	11	19	-23	7.55	-20	17	12	15	13
Changes in Operating Assets and Liabilities, net	28	0.80	7.76	-27	-8.04	-24	33	10	-17	-18	-46
Net Cash From Investing Activities	-34	-13	-24	30	52	3.70	36	7.94	-32	36	75
Net Cash From Continuing Investing Activities	-34	-13	-24	30	52	3.70	36	7.94	-32	36	75
Purchase of Property, Plant & Equipment	-27	-20	-14	-24	-20	-19	-16	-11	-13	-8.93	-9.84
Acquisitions	-2.20	-3.54	-4.04	-5.91	-4.91	-7.14	-1.67	-1.88	-2.55	-2.45	-0.25
Purchase of Investments	-170	-216	-284	-254	-168	-177	-155	-171	-135	-36	-112
Sale and/or Maturity of Investments	160	220	268	307	233	197	202	190	113	83	153
Other Investing Activities, net	5.00	7.33	10	7.17	13	9.40	6.56	1.02	5.43	0.92	44
Net Cash From Financing Activities	0.42	6.63	3.77	2.83	2.65	3.15	4.14	5.97	-3.38	7.37	4.12
Net Cash From Continuing Financing Activities	0.42	6.63	3.77	2.83	2.65	3.15	4.14	5.97	-3.38	7.37	4.12
Other Financing Activities, net	0.42	0.07	10	2.83	0.28	0.04	12	5.97	-3.38	7.37	4.12
Effect of Exchange Rate Changes	0.80	-1.06	1.07	-0.78	-0.04	0.37	-2.16	0.59	0.76	-0.54	0.29

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1,006	1,319	1,541	1,488	1,361	1,357
Total Current Assets	813	930	1,025	872	751	728
Cash & Equivalents	594	476	387	133	156	129
Restricted Cash	-	25	25	25	25	25
Short-Term Investments	0.00	247	500	627	469	405
Accounts Receivable	213	161	39	31	34	58
Other Current Assets	5.97	21	75	56	67	111
Plant, Property, & Equipment, net	18	112	0.00	0.00	0.00	0.00
Total Noncurrent Assets	174	277	515	616	609	629
Long-Term Investments	19	50	73	66	82	63
Goodwill	32	48	48	48	48	48
Intangible Assets	115	148	132	120	42	38
Other Noncurrent Operating Assets	8.39	31	264	382	437	480
Total Liabilities & Shareholders' Equity	1,006	1,319	1,541	1,488	1,361	1,357
Total Liabilities	175	293	308	336	304	390
Total Current Liabilities	103	121	118	119	77	64
Short-Term Debt	13	23	44	50	8.09	0.00
Accounts Payable	20	32	52	50	55	51
Current Deferred Revenue	6.59	7.54	22	19	14	14
Total Noncurrent Liabilities	72	172	189	217	228	326
Noncurrent Deferred & Payable Income Tax Liabilities	26	37	33	31	10	9.12
Other Noncurrent Operating Liabilities	45	107	137	178	218	317
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	831	1,026	1,233	1,152	1,056	967
Total Preferred & Common Equity	831	1,026	1,233	1,152	1,056	967
Total Common Equity	831	1,026	1,233	1,152	1,056	967
Common Stock	716	758	808	874	944	1,001
Retained Earnings	114	268	426	280	117	-29
Accumulated Other Comprehensive Income / (Loss)	0.00	0.28	-1.39	-1.72	-4.38	-4.23

This table presents AbCellera Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	1,594	1,552	1,498	1,537	1,512	1,463	1,412	1,393	1,344	1,402	1,356
Total Current Assets	1,144	1,046	941	931	920	814	772	743	765	742	695
Cash & Equivalents	791	372	193	180	172	124	148	127	159	92	83
Restricted Cash	25	25	25	25	25	25	25	25	25	25	25
Short-Term Investments	232	496	603	616	613	574	522	516	446	461	413
Accounts Receivable	53	106	20	46	37	34	36	31	40	47	41
Other Current Assets	44	46	99	64	71	57	40	43	95	117	133
Plant, Property, & Equipment, net	149	201	233	260	277	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	301	306	324	347	315	649	641	650	579	660	661
Long-Term Investments	66	67	58	59	63	72	76	84	82	90	93
Goodwill	48	48	48	48	48	48	48	48	48	48	48
Intangible Assets	143	143	129	127	124	119	86	53	41	40	39
Other Noncurrent Operating Assets	44	49	90	113	81	411	431	465	409	481	480
Total Liabilities & Shareholders' Equity	1,594	1,552	1,498	1,537	1,512	1,463	1,412	1,393	1,344	1,402	1,356
Total Liabilities	381	302	289	342	329	333	302	315	321	395	392
Total Current Liabilities	221	106	90	119	110	105	70	80	75	67	69
Short-Term Debt	34	33	43	55	54	51	20	20	8.77	0.00	0.00
Accounts Payable	24	26	32	52	36	43	44	54	48	50	53
Current Deferred Revenue	4.62	6.82	12	8.54	18	11	6.40	5.58	19	17	16
Total Noncurrent Liabilities	160	196	200	223	219	228	231	235	246	328	323
Noncurrent Deferred Revenue	-	-	25	28	16	8.57	7.97	8.10	14	12	5.85
Noncurrent Deferred & Payable Income Tax Liabilities	35	34	33	33	33	30	22	13	10	10	9.74
Other Noncurrent Operating Liabilities	125	162	141	163	170	189	201	214	222	306	308
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,213	1,250	1,209	1,195	1,183	1,130	1,111	1,078	1,023	1,007	964
Total Preferred & Common Equity	1,213	1,250	1,209	1,195	1,183	1,130	1,111	1,078	1,023	1,007	964
Total Common Equity	1,213	1,250	1,209	1,195	1,183	1,130	1,111	1,078	1,023	1,007	964
Common Stock	783	795	824	841	857	893	911	928	959	973	987
Retained Earnings	429	456	386	356	327	239	202	151	71	37	-21
Accumulated Other Comprehensive Income / (Loss)	0.58	-0.72	-2.02	-1.90	-1.46	-1.82	-2.07	-1.23	-7.00	-2.66	-2.70

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	1,907.88%	60.92%	29.38%	-92.17%	-24.17%	160.56%
EBITDA Growth	0.00%	29,867.05%	50.86%	9.89%	-172.38%	23.47%	-24.83%
EBIT Growth	0.00%	6,406.85%	44.63%	3.34%	-196.98%	-10.45%	13.79%
NOPAT Growth	0.00%	4,179.26%	21.76%	0.28%	-215.68%	-32.70%	31.03%
Net Income Growth	0.00%	5,478.47%	29.05%	3.29%	-192.35%	-11.24%	10.10%
EPS Growth	0.00%	4,600.00%	6.67%	4.17%	-202.00%	-7.84%	10.91%
Operating Cash Flow Growth	0.00%	742.24%	977.94%	13.40%	-115.82%	-147.41%	-20.95%
Free Cash Flow Firm Growth	0.00%	0.00%	209.14%	-18.56%	-322.85%	10.50%	17.03%
Invested Capital Growth	0.00%	0.00%	8.60%	17.22%	19.69%	-5.70%	4.30%
Revenue Q/Q Growth	0.00%	0.00%	-13.63%	-19.52%	-24.54%	-12.53%	112.69%
EBITDA Q/Q Growth	0.00%	0.00%	-22.51%	-30.18%	-16.29%	5.88%	11.98%
EBIT Q/Q Growth	0.00%	0.00%	-24.48%	-35.22%	-10.03%	1.68%	12.74%
NOPAT Q/Q Growth	0.00%	0.00%	-30.84%	-38.85%	-13.53%	-2.18%	16.91%
Net Income Q/Q Growth	0.00%	0.00%	-27.10%	-36.17%	-13.36%	7.36%	14.72%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-37.50%	-13.33%	8.33%	14.04%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-6.85%	20.73%	-760.20%	9.66%	-25.58%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	31.28%	-20.05%	-0.79%	11.06%
Invested Capital Q/Q Growth	0.00%	0.00%	52.17%	-9.08%	-3.23%	-4.28%	-1.30%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-4.47%	66.26%	62.12%	52.76%	-487.53%	-492.04%	-235.74%
Operating Margin	-35.45%	66.92%	54.48%	44.60%	-623.82%	-1,091.69%	-288.98%
EBIT Margin	-20.38%	64.00%	57.52%	45.94%	-568.77%	-828.45%	-274.10%
Profit (Net Income) Margin	-19.04%	51.00%	40.90%	32.66%	-385.00%	-564.83%	-194.88%
Tax Burden Percent	100.00%	75.34%	70.03%	66.30%	84.12%	81.27%	82.44%
Interest Burden Percent	93.45%	105.77%	101.54%	107.21%	80.47%	83.89%	86.24%
Effective Tax Rate	0.00%	24.66%	29.97%	33.70%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	101.98%	59.53%	52.79%	-51.51%	-64.56%	-44.91%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	101.53%	58.03%	51.04%	-53.76%	-72.10%	-45.74%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-73.34%	-42.99%	-38.75%	39.23%	49.82%	30.44%
Return on Equity (ROE)	0.00%	28.64%	16.53%	14.03%	-12.27%	-14.75%	-14.47%
Cash Return on Invested Capital (CROIC)	0.00%	-98.02%	51.29%	36.94%	-69.43%	-58.70%	-49.12%
Operating Return on Assets (OROA)	0.00%	14.84%	18.57%	15.60%	-14.28%	-16.77%	-15.16%
Return on Assets (ROA)	0.00%	11.83%	13.21%	11.09%	-9.67%	-11.43%	-10.78%
Return on Common Equity (ROCE)	0.00%	28.64%	16.53%	14.03%	-12.27%	-14.75%	-14.47%
Return on Equity Simple (ROE_SIMPLE)	0.00%	14.32%	14.96%	12.85%	-12.70%	-15.42%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.88	118	143	144	-166	-220	-152
NOPAT Margin	-24.82%	50.42%	38.15%	29.57%	-436.67%	-764.18%	-202.28%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.45%	1.50%	1.75%	2.26%	7.53%	0.83%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	11.24%	-13.80%	-20.71%	-15.72%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	23.67%	5.11%	11.15%	11.43%	160.42%	252.18%	110.79%
R&D to Revenue	87.09%	12.61%	16.54%	22.22%	461.95%	580.10%	248.68%
Operating Expenses to Revenue	135.45%	29.51%	45.52%	55.40%	723.82%	1,191.69%	388.98%
Earnings before Interest and Taxes (EBIT)	-2.37	149	216	223	-216	-239	-206
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.52	154	233	256	-185	-142	-177
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.17	3.93	2.35	1.44	0.82	1.06
Price to Tangible Book Value (P/TBV)	0.00	1.42	4.85	2.75	1.68	0.90	1.16
Price to Revenue (P/Rev)	41.59	4.17	10.73	5.97	43.57	30.02	13.63
Price to Earnings (P/E)	0.00	8.17	26.24	18.28	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	12.24%	3.81%	5.47%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.61	12.99	6.67	2.44	0.42	1.16
Enterprise Value to Revenue (EV/Rev)	0.00	1.59	8.67	4.03	22.51	4.88	5.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	2.41	13.95	7.65	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	2.49	15.06	8.78	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	3.16	22.71	13.64	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	16.39	13.29	7.06	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	26.36	19.50	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	0.02	0.02	0.04	0.04	0.01	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.72	-0.74	-0.76	-0.73	-0.69	-0.67
Leverage Ratio	0.00	1.21	1.25	1.27	1.27	1.29	1.34
Compound Leverage Factor	0.00	1.28	1.27	1.36	1.02	1.08	1.16
Debt to Total Capital	0.00%	1.59%	2.19%	3.46%	4.20%	0.76%	0.00%
Short-Term Debt to Total Capital	0.00%	1.59%	2.19%	3.46%	4.20%	0.76%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	98.41%	97.81%	96.54%	95.80%	99.24%	100.00%
Debt to EBITDA	0.00	0.09	0.10	0.17	-0.27	-0.06	0.00
Net Debt to EBITDA	0.00	-3.88	-3.33	-3.67	4.32	5.11	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.11	0.16	0.31	-0.30	-0.04	0.00
Net Debt to NOPAT	0.00	-5.10	-5.42	-6.55	4.82	3.29	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	5.06	10.10	7.54	3.38	1.86	1.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	7.86	7.70	8.67	7.33	9.81	11.32
Quick Ratio	0.00	7.80	7.32	7.82	6.65	8.60	9.21
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-113	123	100	-224	-200	-166
Operating Cash Flow to CapEx	67.40%	234.57%	418.44%	392.53%	-57.02%	-138.47%	-306.96%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.23	0.32	0.34	0.03	0.02	0.06
Accounts Receivable Turnover	0.00	1.09	2.01	4.87	1.10	0.90	1.63
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	13.01	5.79	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	333.82	181.82	74.88	332.04	406.40	223.26
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	333.82	181.82	74.88	332.04	406.40	223.26
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	231	250	293	351	331	345
Invested Capital Turnover	0.00	2.02	1.56	1.79	0.12	0.08	0.22
Increase / (Decrease) in Invested Capital	0.00	231	20	43	58	-20	14
Enterprise Value (EV)	0.00	372	3,251	1,958	856	141	402
Market Capitalization	483	972	4,027	2,898	1,657	865	1,024
Book Value per Share	$0.00	$5.22	$3.64	$4.31	$3.97	$3.58	$3.23
Tangible Book Value per Share	$0.00	$4.30	$2.95	$3.68	$3.39	$3.27	$2.94
Total Capital	0.00	844	1,049	1,277	1,203	1,064	967
Total Debt	0.00	13	23	44	50	8.09	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-600	-775	-940	-801	-725	-621
Capital Expenditures (CapEx)	4.00	9.67	58	71	77	78	43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	129	84	40	18	32	105
Debt-free Net Working Capital (DFNWC)	0.00	723	832	951	803	683	664
Net Working Capital (NWC)	0.00	710	809	907	753	675	664
Net Nonoperating Expense (NNE)	-0.67	-1.36	-10	-15	-20	-57	-5.56
Net Nonoperating Obligations (NNO)	0.00	-600	-775	-940	-801	-725	-621
Total Depreciation and Amortization (D&A)	1.85	5.27	17	33	31	97	29
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	55.38%	22.41%	8.22%	46.97%	111.79%	139.89%
Debt-free Net Working Capital to Revenue	0.00%	310.20%	221.76%	195.99%	2,112.94%	2,368.28%	883.73%
Net Working Capital to Revenue	0.00%	304.45%	215.65%	186.88%	1,980.20%	2,340.23%	883.73%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.56	$0.56	($0.51)	($0.55)	($0.49)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	275.76M	285.06M	289.17M	294.33M	298.71M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.48	$0.50	($0.51)	($0.55)	($0.49)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	318.29M	314.83M	289.17M	294.33M	298.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	283.92M	287.69M	292.78M	297.99M	303.16M
Normalized Net Operating Profit after Tax (NOPAT)	-2.88	118	143	144	-166	-220	-152
Normalized NOPAT Margin	-24.82%	50.42%	38.15%	29.57%	-436.67%	-764.18%	-202.28%
Pre Tax Income Margin	-19.04%	67.69%	58.41%	49.26%	-457.67%	-695.02%	-236.39%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AbCellera Biologics' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-78.10%	-93.49%	-57.40%	-18.36%	-27.18%	-1.39%	-44.99%	-57.45%	133.29%	37.62%	788.37%
EBITDA Growth	-1,738.29%	-189.21%	-106.01%	8.67%	51.96%	20.34%	17.57%	-17.35%	-84.83%	-101.23%	57.93%
EBIT Growth	-487.75%	-221.90%	-49.47%	8.22%	-18.87%	-44.42%	6.84%	-14.84%	24.23%	-4.57%	54.20%
NOPAT Growth	-512.07%	-278.17%	-74.85%	15.38%	-81.86%	-70.64%	-10.14%	-14.15%	46.94%	18.56%	60.72%
Net Income Growth	-349.93%	-207.46%	-57.73%	-1.25%	-20.97%	-78.63%	27.44%	-12.34%	5.97%	-11.76%	73.85%
EPS Growth	-450.00%	-225.00%	-60.00%	0.00%	-18.18%	-70.00%	31.25%	-7.14%	7.69%	-11.76%	72.73%
Operating Cash Flow Growth	-92.71%	99.92%	-163.44%	5.34%	-250.56%	-27,147.17%	59.21%	72.30%	-8.14%	-82.10%	-334.29%
Free Cash Flow Firm Growth	-6,769.53%	42.48%	-49.57%	-0.41%	79.87%	38.09%	70.28%	143.41%	74.88%	-17.87%	-10.76%
Invested Capital Growth	176.24%	12.45%	19.69%	3.88%	-2.87%	-4.65%	-5.70%	-17.28%	-5.83%	1.15%	4.30%
Revenue Q/Q Growth	-17.52%	-34.38%	39.08%	8.46%	-26.43%	-11.14%	-22.41%	-16.12%	303.40%	-47.58%	400.88%
EBITDA Q/Q Growth	18.23%	-2.60%	-18.43%	8.08%	56.99%	-70.12%	-22.56%	-30.85%	32.25%	-85.21%	74.38%
EBIT Q/Q Growth	15.76%	-2.53%	-19.10%	10.78%	-9.11%	-24.57%	23.17%	-9.98%	28.02%	-71.92%	66.35%
NOPAT Q/Q Growth	20.79%	-6.81%	-20.34%	16.90%	-70.24%	-0.22%	22.32%	13.88%	20.87%	-53.83%	62.53%
Net Income Q/Q Growth	23.89%	6.28%	-64.80%	13.87%	9.06%	-38.39%	33.06%	-33.36%	23.88%	-64.48%	84.34%
EPS Q/Q Growth	21.43%	9.09%	-60.00%	12.50%	7.14%	-30.77%	35.29%	-36.36%	20.00%	-58.33%	84.21%
Operating Cash Flow Q/Q Growth	145.17%	-100.53%	-18,400.94%	-112.68%	28.15%	3.62%	72.30%	-44.43%	-180.46%	-62.31%	33.94%
Free Cash Flow Firm Q/Q Growth	-417.05%	71.11%	-32.31%	49.19%	-3.63%	11.14%	36.48%	174.22%	-159.96%	-316.99%	40.31%
Invested Capital Q/Q Growth	-0.56%	-1.96%	-3.23%	10.09%	-7.02%	-3.75%	-4.28%	-3.42%	5.85%	3.38%	-1.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-412.96%	-645.66%	-549.80%	-465.96%	-272.44%	-521.59%	-823.87%	-1,285.24%	-215.85%	-762.67%	-39.02%
Operating Margin	-511.03%	-831.79%	-719.70%	-551.48%	-1,276.17%	-1,439.42%	-1,440.98%	-1,479.58%	-290.24%	-851.79%	-63.72%
EBIT Margin	-485.11%	-757.93%	-649.05%	-533.94%	-791.86%	-1,110.11%	-1,099.17%	-1,441.20%	-257.18%	-843.47%	-56.67%
Profit (Net Income) Margin	-303.58%	-433.55%	-513.73%	-407.98%	-504.30%	-785.42%	-677.56%	-1,077.24%	-203.27%	-637.84%	-19.94%
Tax Burden Percent	80.33%	72.84%	97.01%	95.00%	76.64%	81.60%	73.05%	86.10%	95.55%	83.06%	45.87%
Interest Burden Percent	77.90%	78.53%	81.59%	80.43%	83.10%	86.71%	84.38%	86.81%	82.72%	91.04%	76.71%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-205.98%	-85.57%	-59.42%	-36.40%	-80.92%	-93.68%	-85.22%	-67.75%	-19.13%	-60.51%	-9.90%
ROIC Less NNEP Spread (ROIC-NNEP)	-206.56%	-86.69%	-59.32%	-36.13%	-84.54%	-95.54%	-87.41%	-67.51%	-19.13%	-59.95%	-11.55%
Return on Net Nonoperating Assets (RNNOA)	163.30%	62.26%	43.29%	24.40%	57.78%	65.58%	60.40%	45.35%	12.82%	39.52%	7.68%
Return on Equity (ROE)	-42.69%	-23.31%	-16.14%	-12.00%	-23.14%	-28.10%	-24.82%	-22.40%	-6.31%	-20.99%	-2.22%
Cash Return on Invested Capital (CROIC)	-125.98%	-54.38%	-69.43%	-45.71%	-48.74%	-56.06%	-58.70%	-44.99%	-49.87%	-53.69%	-49.12%
Operating Return on Assets (OROA)	-44.99%	-24.92%	-16.30%	-12.91%	-17.75%	-25.19%	-22.25%	-23.73%	-6.01%	-21.68%	-3.13%
Return on Assets (ROA)	-28.15%	-14.26%	-12.90%	-9.86%	-11.30%	-17.82%	-13.72%	-17.74%	-4.75%	-16.39%	-1.10%
Return on Common Equity (ROCE)	-42.69%	-23.31%	-16.14%	-12.00%	-23.14%	-28.10%	-24.82%	-22.40%	-6.31%	-20.99%	-2.22%
Return on Equity Simple (ROE_SIMPLE)	-6.19%	-10.92%	0.00%	-13.00%	-13.80%	-16.31%	0.00%	-16.41%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-36	-38	-46	-38	-65	-66	-51	-44	-35	-53	-20
NOPAT Margin	-357.72%	-582.25%	-503.79%	-386.03%	-893.32%	-1,007.59%	-1,008.68%	-1,035.70%	-203.17%	-596.25%	-44.60%
Net Nonoperating Expense Percent (NNEP)	0.57%	1.12%	-0.10%	-0.28%	3.62%	1.86%	2.19%	-0.24%	0.00%	-0.55%	1.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-3.84%	-	-	-	-4.79%	-4.25%	-3.45%	-5.54%	-2.07%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	154.35%	217.75%	174.06%	174.32%	275.73%	294.25%	317.29%	383.14%	111.08%	246.25%	57.91%
R&D to Revenue	362.70%	574.59%	529.76%	394.69%	558.88%	629.61%	912.58%	1,003.45%	229.53%	614.49%	111.68%
Operating Expenses to Revenue	611.03%	931.79%	819.70%	651.48%	1,376.17%	1,539.42%	1,540.98%	1,579.58%	390.24%	951.79%	163.72%
Earnings before Interest and Taxes (EBIT)	-49	-50	-60	-53	-58	-72	-55	-61	-44	-76	-25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-43	-50	-46	-20	-34	-42	-54	-37	-68	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.56	1.13	1.44	1.16	0.78	0.71	0.82	0.65	1.02	1.56	1.06
Price to Tangible Book Value (P/TBV)	1.83	1.32	1.68	1.36	0.89	0.78	0.90	0.71	1.11	1.71	1.16
Price to Revenue (P/Rev)	12.85	26.41	43.57	36.73	26.33	23.24	30.02	28.75	31.14	42.55	13.63
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.81	1.41	2.44	1.48	0.33	0.10	0.42	0.00	1.05	2.54	1.16
Enterprise Value to Revenue (EV/Rev)	7.17	10.15	22.51	15.96	3.60	1.04	4.88	0.00	10.81	25.17	5.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	76.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.05	0.05	0.04	0.05	0.02	0.02	0.01	0.01	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.79	-0.72	-0.73	-0.68	-0.68	-0.69	-0.69	-0.67	-0.67	-0.66	-0.67
Leverage Ratio	1.30	1.26	1.27	1.27	1.28	1.28	1.29	1.30	1.33	1.35	1.34
Compound Leverage Factor	1.01	0.99	1.04	1.02	1.06	1.11	1.09	1.13	1.10	1.23	1.03
Debt to Total Capital	4.39%	4.36%	4.20%	4.35%	1.77%	1.84%	0.76%	0.85%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	4.39%	4.36%	4.20%	4.35%	1.77%	1.84%	0.76%	0.85%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	95.61%	95.64%	95.80%	95.65%	98.23%	98.16%	99.24%	99.15%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.79	-0.34	-0.27	-0.28	-0.13	-0.13	-0.06	-0.06	0.00	0.00	0.00
Net Debt to EBITDA	11.94	5.14	4.32	4.11	4.71	4.86	5.11	4.69	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.67	-0.37	-0.30	-0.32	-0.11	-0.09	-0.04	-0.04	0.00	0.00	0.00
Net Debt to NOPAT	10.13	5.61	4.82	4.67	3.99	3.39	3.29	3.11	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.22	3.29	3.72	3.08	2.42	2.04	2.31	1.80	2.09	2.68	2.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.83	8.34	7.33	7.76	10.96	9.34	9.81	10.15	11.07	10.10	11.32
Quick Ratio	7.08	7.47	6.65	6.98	10.04	8.48	8.60	8.56	8.96	7.81	9.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-272	-79	-104	-53	-55	-49	-31	23	-14	-57	-34
Operating Cash Flow to CapEx	73.17%	-0.52%	-135.89%	-172.78%	-149.01%	-155.98%	-51.18%	-108.63%	-242.45%	-589.09%	-352.97%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.09	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.06
Accounts Receivable Turnover	2.95	0.70	1.10	1.32	0.81	0.96	0.90	0.62	0.79	0.97	1.63
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.71	0.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	123.79	519.40	332.04	277.53	451.76	381.03	406.40	587.63	463.28	376.28	223.26
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	123.79	519.40	332.04	277.53	451.76	381.03	406.40	587.63	463.28	376.28	223.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	370	363	351	387	360	346	331	320	339	350	345
Invested Capital Turnover	0.58	0.15	0.12	0.09	0.09	0.09	0.08	0.07	0.09	0.10	0.22
Increase / (Decrease) in Invested Capital	236	40	58	14	-11	-17	-20	-67	-21	3.98	14
Enterprise Value (EV)	1,041	511	856	571	119	34	141	-39	355	889	402
Market Capitalization	1,865	1,331	1,657	1,314	870	766	865	665	1,024	1,503	1,024
Book Value per Share	$4.14	$4.09	$3.97	$3.86	$3.78	$3.66	$3.58	$3.43	$3.37	$3.23	$3.23
Tangible Book Value per Share	$3.53	$3.49	$3.39	$3.29	$3.32	$3.32	$3.27	$3.13	$3.08	$2.93	$2.94
Total Capital	1,250	1,237	1,203	1,181	1,131	1,098	1,064	1,032	1,007	964	967
Total Debt	55	54	50	51	20	20	8.09	8.77	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-825	-820	-801	-743	-751	-732	-725	-703	-668	-614	-621
Capital Expenditures (CapEx)	27	20	14	24	20	19	16	11	13	8.93	9.84
Debt-free, Cash-free Net Working Capital (DFCFNWC)	46	52	18	37	26	15	32	68	97	106	105
Debt-free Net Working Capital (DFNWC)	867	863	803	760	721	684	683	698	675	626	664
Net Working Capital (NWC)	812	809	753	709	701	663	675	690	675	626	664
Net Nonoperating Expense (NNE)	-5.44	-9.81	0.91	2.18	-28	-14	-17	1.76	0.02	3.72	-11
Net Nonoperating Obligations (NNO)	-825	-820	-801	-743	-751	-732	-725	-703	-668	-614	-621
Total Depreciation and Amortization (D&A)	7.26	7.41	9.11	6.77	38	38	14	6.61	7.06	7.24	7.92
Debt-free, Cash-free Net Working Capital to Revenue	31.69%	103.93%	46.97%	104.71%	78.19%	46.70%	111.79%	294.57%	295.19%	299.14%	139.89%
Debt-free Net Working Capital to Revenue	597.01%	1,713.05%	2,112.94%	2,125.06%	2,181.89%	2,073.70%	2,368.28%	3,021.34%	2,053.60%	1,773.17%	883.73%
Net Working Capital to Revenue	559.21%	1,606.03%	1,980.20%	1,981.35%	2,121.30%	2,012.36%	2,340.23%	2,983.40%	2,053.60%	1,773.17%	883.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)	($0.15)	($0.12)	($0.19)	($0.03)
Adjusted Weighted Average Basic Shares Outstanding	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M	297.69M	298.51M	298.88M	298.71M
Adjusted Diluted Earnings per Share	($0.11)	($0.10)	($0.16)	($0.14)	($0.13)	($0.17)	($0.11)	($0.15)	($0.12)	($0.19)	($0.03)
Adjusted Weighted Average Diluted Shares Outstanding	288.91M	289.50M	289.17M	292.72M	294.22M	294.85M	294.33M	297.69M	298.51M	298.88M	298.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	289.36M	290.17M	292.78M	294.05M	294.67M	295.37M	297.99M	298.48M	298.83M	299.34M	303.16M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-38	-46	-38	-65	-66	-51	-44	-35	-53	-20
Normalized NOPAT Margin	-357.72%	-582.25%	-503.79%	-386.03%	-893.32%	-1,007.59%	-1,008.68%	-1,035.70%	-203.17%	-596.25%	-44.60%
Pre Tax Income Margin	-377.92%	-595.18%	-529.54%	-429.45%	-658.02%	-962.53%	-927.49%	-1,251.10%	-212.74%	-767.93%	-43.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are a concise set of takeaways for AbCellera Biologics (ABCL) based on the quarterly financials provided (latest Q4 2025 and prior four years). Below are the top 10 items, with positives listed first, followed by neutrals, then negatives.

Q4 2025 revenue spike: Operating revenue and total revenue reached 44,854,000 USD in Q4 2025, a sharp rise from earlier quarters and a notable quarterly uptick.
Major cash inflow from investing activities in Q4 2025: Net cash from continuing investing activities was 75,138,000 USD, driven by the sale/maturity of investments.
Improved quarterly cash position in Q4 2025: Net change in cash and equivalents was an increase of 44,800,000 USD for the quarter, signaling improved liquidity that quarter.
Modest financing support in Q4 2025: Net cash from financing activities was 4,115,000 USD, providing some financing cushion during the quarter.
Strong liquidity snapshot in Q3 2025: At end-Q3 2025, the company held cash of 83,159,000 USD and short-term investments of 412,513,000 USD, with total current assets of 695,140,000 USD, implying a sizable liquidity cushion; there were no short-term debts then.
Revenue volatility across quarters: ABCL’s topline has fluctuated (examples include Q3 2025: 8.96M, Q4 2025: 44.85M, Q2 2025: 17.08M, Q1 2025: 4.24M), indicating variability in quarterly demand or recognition.
Heavy but ongoing R&D investment: Research & Development expenses run high each quarter (Q4 2025: 50.09M; Q3 2025: 55.03M; Q2 2025: 39.21M; Q1 2025: 42.50M), reflecting a persistent focus on pipeline development.
Steady, sizable share count with ongoing losses: Weighted average shares outstanding are in the 298–303 million range across 2025, with basic and diluted earnings per share reported as negative (e.g., Q4 2025 EPS -0.03).
Persistent net losses: Net income from continuing operations was negative across recent quarters (Q4 2025 Consolidated Net Income -8.95M; Q3 2025 -57.12M; Q2 2025 -34.73M; Q1 2025 -45.62M).
Negative operating income in multiple quarters: Total Operating Income was negative in several periods (Q4 2025: -28.58M; Q3 2025: -76.28M), indicating ongoing operating losses despite revenue entries.

05/07/26 08:07 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About AbCellera Biologics' Financials

When does AbCellera Biologics' fiscal year end?

According to the most recent income statement we have on file, AbCellera Biologics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has AbCellera Biologics' net income changed over the last 6 years?

AbCellera Biologics' net income appears to be on an upward trend, with a most recent value of -$146.41 million in 2025, rising from -$2.21 million in 2019. The previous period was -$162.86 million in 2024. View AbCellera Biologics' forecast to see where analysts expect AbCellera Biologics to go next.

What is AbCellera Biologics' operating income?

AbCellera Biologics' total operating income in 2025 was -$217.10 million, based on the following breakdown:

Total Gross Profit: $75.13 million
Total Operating Expenses: $292.23 million

How has AbCellera Biologics' revenue changed over the last 6 years?

Over the last 6 years, AbCellera Biologics' total revenue changed from $11.61 million in 2019 to $75.13 million in 2025, a change of 547.0%.

How much debt does AbCellera Biologics have?

AbCellera Biologics' total liabilities were at $390.05 million at the end of 2025, a 28.1% increase from 2024, and a 122.8% increase since 2020.

How much cash does AbCellera Biologics have?

In the past 5 years, AbCellera Biologics' cash and equivalents has ranged from $128.51 million in 2025 to $594.12 million in 2020, and is currently $128.51 million as of their latest financial filing in 2025.

How has AbCellera Biologics' book value per share changed over the last 6 years?

Over the last 6 years, AbCellera Biologics' book value per share changed from 0.00 in 2019 to 3.23 in 2025, a change of 323.0%.

Related Companies

Financial statements for NASDAQ:ABCL last updated on 2/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About AbCellera Biologics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Financials

Annual Income Statements for AbCellera Biologics

Quarterly Income Statements for AbCellera Biologics

Annual Cash Flow Statements for AbCellera Biologics

Quarterly Cash Flow Statements for AbCellera Biologics

Annual Balance Sheets for AbCellera Biologics

Quarterly Balance Sheets for AbCellera Biologics

Annual Metrics And Ratios for AbCellera Biologics

Quarterly Metrics And Ratios for AbCellera Biologics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About AbCellera Biologics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools